Drug Dependence Clinical Trial
Official title:
Brain Activation in Response to Motivational and Affective Stimuli: Pharmacological Manipulations
Verified date | June 25, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study seeks more information about the biology of substance dependency by exploring the
brain areas involved in feeling positive and negative emotions. Specifically, it will
determine whether a brain chemical called dopamine affects activity in certain brain regions
during performance of a game that involves winning and losing money. Brain activity will be
examined using magnetic resonance imaging (MRI), a test that uses a magnetic field and radio
waves to produce images of brain structure and function.
Young to middle-aged healthy adults may participate in this study. Candidates will be
screened with a medical history, physical examination, electrocardiogram (EKG), psychiatric
interview, and blood and urine tests. Participants will be assigned to one of the two study
procedures, as follows:
Tyrosine/Phenylalanine
This study requires two overnight stays at the NIH Clinical Center. For each stay, subjects
are admitted to the hospital the afternoon before the MRI scan. From the time of admission
until after the scan, their diets are restricted to food relatively low in amino acids,
prepared by NIH dietitians. The next day, participants undergo MRI scanning. For this
procedure, the subject lies on a table that is moved into the scanner, a metal cylindrical
machine. Earplugs are worn to muffle loud noises that occur with electrical switching of the
radio frequency circuits. Imaging of brain structure takes about 10 to 15 minutes. Additional
scans are then taken to measure brain activity while the subject plays simple computer games
for money. These scans take about another 20 to 45 minutes. Five hours before the MRI, the
subject drinks one of two beverages containing amino acids. A different beverage is given for
each of the two visits: one drink lacks the essential amino acids tyrosine and phenylalanine,
from which the body makes dopamine; the other contains balanced amounts of these two amino
acids. Finally, subjects fill out mood-rating questionnaires before and after drinking each
of the beverages.
Dextroamphetamine
This study requires two outpatient visits to the NIH Clinical Center. For one visit,
participants are given an injection of 0.2 mg/kg body weight of the drug dextroamphetamine;
for the other, they are given an injection of saline (salt water). After each injection, they
undergo MRI scanning while playing computer games for money, as described above. They will
fill out mood-rating questionnaires before and after each brain scan.
Status | Completed |
Enrollment | 38 |
Est. completion date | June 25, 2010 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION AND EXCLUSION CRITERIA: Subjects are physically healthy as determined by medical evaluation at the NIAAA outpatient clinic. In particular, subjects must demonstrate no cardiovascular or blood pressure abnormalities, such as a resting blood pressure of 140/90 or greater. All values of laboratory test must be within the NIH defined normal range and all radiological and cardiac evaluations must be considered normal by the NIH radiologist or cardiologist reading the scan or record. As is usual clinical practice, in the case of minor abnormalities a lab test may be repeated to ensure the validity of the initial report. Are between 18-65 years of age. Have 20/20 vision or wear corrective contact lenses. Plastic glasses with pop-in lenses of different strengths are available in the NMR center for use with nearsighted subjects who do not wear contacts. Have no ferromagnetic objects in their bodies which might be adversely affected by MRI (e.g. surgical clips; metal fragments in or near brain; eye or blood vessels; cardiac or neurological pacemaker; cochlear or eye implant - any doubt about absence of these objects will result in exclusion from this study). Test HIV negative. Have no indication of any organic brain syndrome. Do not meet criteria for any present or past Axis I psychiatric disorder, including nicotine dependence. Smokers will be excluded. Have no active homicidal or suicidal ideation, or active symptoms of post-traumatic stress disorder. Are not currently receiving psychotropic medication or medication likely to affect brain neurotransmitter systems. Have no indication of recent drug use as evidenced by urine drug screen and self-report. Are not pregnant or lactating. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
United States,
Holland P, Mushinski M. Costs of alcohol and drug abuse in the United States, 1992. Alcohol/Drugs COI Study Team. Stat Bull Metrop Insur Co. 1999 Oct-Dec;80(4):2-9. — View Citation
Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci. 2000;909:170-85. Review. — View Citation
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997 Apr 24;386(6627):830-3. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT00593463 -
Drug Discrimination in Methadone-Maintained Humans Study 1
|
Phase 1 | |
Completed |
NCT03678051 -
CBT4CBT for Women in Residential Treatment for Substance Use Disorders
|
N/A | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01449981 -
Development and Testing of Adolescent Twelve-Step Facilitation
|
N/A | |
Completed |
NCT00183118 -
Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03333460 -
Transcranial Magnetic Stimulation for Cocaine Addiction
|
N/A | |
Completed |
NCT02124980 -
Automated Recovery Line for Medication Assisted Treatment
|
N/A | |
Terminated |
NCT00975416 -
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
|
Phase 4 | |
Completed |
NCT00265512 -
LINK: Aftercare Monitoring Project
|
N/A | |
Completed |
NCT00706901 -
Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Withdrawn |
NCT00675532 -
Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).
|
N/A | |
Active, not recruiting |
NCT03539575 -
CB1R in Synthetic Psychoactive Cannabinoids
|
N/A | |
Completed |
NCT01246401 -
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
|
Phase 1/Phase 2 | |
Completed |
NCT01096550 -
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
|
N/A | |
Completed |
NCT00605033 -
A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
|
Phase 4 |